Establishment of a human pancreatic tumor xenograft model: potential application for preclinical evaluation of novel therapeutic agents.

@article{Mohammad1998EstablishmentOA,
  title={Establishment of a human pancreatic tumor xenograft model: potential application for preclinical evaluation of novel therapeutic agents.},
  author={R. Mohammad and M. C. Dugan and A. Mohamed and V. P. Almatchy and T. M. Flake and S. Dergham and A. Shields and A. Alkatib and V. Vaitkevicius and F. Sarkar},
  journal={Pancreas},
  year={1998},
  volume={16 1},
  pages={
          19-25
        }
}
  • R. Mohammad, M. C. Dugan, +7 authors F. Sarkar
  • Published 1998
  • Medicine
  • Pancreas
  • Adenocarcinoma of the pancreas is currently the fifth leading cause of death in the United States. It remains generally incurable by available treatment modalities. We report here on the characterization of a permanent pancreatic cell line (KCI-MOH1), established as a xenograft in severe combined immune deficient (SCID) mice, from a 74 year-old African American male patient diagnosed with pancreatic cancer. Sections from paraffin-embedded tumors excised from SCID mice revealed typical… CONTINUE READING
    42 Citations
    An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice: potential application for preclinical studies.
    • 38
    • PDF
    Adjuvant Treatment of Pancreatic Carcinoma in a Clinically Adapted Mouse Resection Model
    • 18
    Successful xenografting of cryopreserved primary pancreatic cancers
    • 34
    The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice
    • 93
    Mice with Spontaneous Pancreatic Cancer Naturally Develop MUC-1-Specific CTLs That Eradicate Tumors When Adoptively Transferred1
    • 95
    • Highly Influenced
    • PDF

    References

    SHOWING 1-10 OF 24 REFERENCES
    Differential effects of bryostatin 1 on human non-Hodgkin's B-lymphoma cell lines.
    • 35
    Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).
    • 654
    A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer.
    • 566
    P53-independent induction of p21(waf1) pathway is preserved during tumor progression.
    • 12
    Bryostatin 1 induces differentiation of B-chronic lymphocytic leukemia cells.
    • 68
    • PDF